Cannabinoid receptor type-1: breaking the dogmas.

Arnau Busquets Garcia, Edgar Soria-Gomez, Luigi Bellocchio, Giovanni Marsicano
F1000Res. 2016-05-24; 5: 990
DOI: 10.12688/f1000research.8245.1

Lire sur PubMed

1. F1000Res. 2016 May 24;5. pii: F1000 Faculty Rev-990. doi:
10.12688/f1000research.8245.1. eCollection 2016.

Cannabinoid receptor type-1: breaking the dogmas.

Busquets Garcia A(1), Soria-Gomez E(1), Bellocchio L(1), Marsicano G(1).

Author information:
(1)Endocannabinoids and Neuroadaptation, INSERM U1215 NeuroCentre Magendie,
Bordeaux, 33077, France; University of Bordeaux, Bordeaux, France.

The endocannabinoid system (ECS) is abundantly expressed in the brain. This
system regulates a plethora of physiological functions and is composed of
cannabinoid receptors, their endogenous ligands (endocannabinoids), and the
enzymes involved in the metabolism of endocannabinoids. In this review, we
highlight the new advances in cannabinoid signaling, focusing on a key component
of the ECS, the type-1 cannabinoid receptor (CB 1). In recent years, the
development of new imaging and molecular tools has demonstrated that this
receptor can be distributed in many cell types (e.g., neuronal or glial cells)
and intracellular compartments (e.g., mitochondria). Interestingly, cellular and
molecular effects are differentially mediated by CB 1 receptors according to
their specific localization (e.g., glutamatergic or GABAergic neurons). Moreover,
this receptor is expressed in the periphery, where it can modulate
periphery-brain connections. Finally, the better understanding of the CB 1
receptor structure led researchers to propose interesting and new allosteric
modulators. Thus, the advances and the new directions of the CB 1 receptor field
will provide new insights and better approaches to profit from its interesting
therapeutic profile.

DOI: 10.12688/f1000research.8245.1
PMCID: PMC4879932
PMID: 27239293

Auteurs Bordeaux Neurocampus